ID   HV270_HUMAN             Reviewed;         119 AA.
AC   P01814; A0A0B4J2H3; P01815; P01816; P04438;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2016, sequence version 2.
DT   07-APR-2021, entry version 113.
DE   RecName: Full=Immunoglobulin heavy variable 2-70 {ECO:0000303|PubMed:11340299, ECO:0000303|Ref.6};
DE   AltName: Full=Ig heavy chain V-II region COR {ECO:0000305|PubMed:5449120};
DE   AltName: Full=Ig heavy chain V-II region DAW {ECO:0000305|PubMed:5449120};
DE   AltName: Full=Ig heavy chain V-II region OU {ECO:0000305|PubMed:4742735};
DE   AltName: Full=Ig heavy chain V-II region SESS {ECO:0000305|PubMed:6089186};
DE   Flags: Precursor;
GN   Name=IGHV2-70 {ECO:0000303|PubMed:11340299, ECO:0000303|Ref.6};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6089186; DOI=10.1073/pnas.81.16.5194;
RA   Takahashi N., Noma T., Honjo T.;
RT   "Rearranged immunoglobulin heavy chain variable region (VH) pseudogene that
RT   deletes the second complementarity-determining region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:5194-5198(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (IMGT ALLELE IGHV2-70*01).
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [3]
RP   PROTEIN SEQUENCE OF 20-119, AND PYROGLUTAMATE FORMATION AT GLN-20.
RX   PubMed=5449120; DOI=10.1042/bj1170641;
RA   Press E.M., Hogg N.M.;
RT   "The amino acid sequences of the Fd fragments of two human gamma-1 heavy
RT   chains.";
RL   Biochem. J. 117:641-660(1970).
RN   [4]
RP   PROTEIN SEQUENCE OF 20-119, AND PYROGLUTAMATE FORMATION AT GLN-20.
RX   PubMed=4742735; DOI=10.1126/science.182.4109.287;
RA   Putnam F.W., Florent G., Paul C., Shinoda T., Shimizu A.;
RT   "Complete amino acid sequence of the Mu heavy chain of a human IgM
RT   immunoglobulin.";
RL   Science 182:287-291(1973).
RN   [5]
RP   NOMENCLATURE.
RX   PubMed=11340299; DOI=10.1159/000049189;
RA   Lefranc M.P.;
RT   "Nomenclature of the human immunoglobulin heavy (IGH) genes.";
RL   Exp. Clin. Immunogenet. 18:100-116(2001).
RN   [6]
RP   NOMENCLATURE.
RA   Lefranc M.P., Lefranc G.;
RT   "The Immunoglobulin FactsBook.";
RL   (In) Lefranc M.P., Lefranc G. (eds.);
RL   The Immunoglobulin FactsBook., pp.1-458, Academic Press, London. (2001).
RN   [7]
RP   REVIEW ON SOMATIC HYPERMUTATION.
RX   PubMed=17576170; DOI=10.1146/annurev.genet.41.110306.130340;
RA   Teng G., Papavasiliou F.N.;
RT   "Immunoglobulin somatic hypermutation.";
RL   Annu. Rev. Genet. 41:107-120(2007).
RN   [8]
RP   REVIEW ON IMMUNOGLOBULINS.
RX   PubMed=20176268; DOI=10.1016/j.jaci.2009.09.046;
RA   Schroeder H.W. Jr., Cavacini L.;
RT   "Structure and function of immunoglobulins.";
RL   J. Allergy Clin. Immunol. 125:S41-S52(2010).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=22158414; DOI=10.1038/nri3128;
RA   McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L.;
RT   "Molecular programming of B cell memory.";
RL   Nat. Rev. Immunol. 12:24-34(2012).
RN   [10]
RP   NOMENCLATURE.
RX   PubMed=24600447; DOI=10.3389/fimmu.2014.00022;
RA   Lefranc M.P.;
RT   "Immunoglobulin and T Cell Receptor Genes: IMGT((R)) and the Birth and Rise
RT   of Immunoinformatics.";
RL   Front. Immunol. 5:22-22(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 20-117, AND DISULFIDE BOND.
RX   PubMed=17947238; DOI=10.1074/jbc.m706190200;
RA   Makabe K., Nakanishi T., Tsumoto K., Tanaka Y., Kondo H., Umetsu M.,
RA   Sone Y., Asano R., Kumagai I.;
RT   "Thermodynamic consequences of mutations in vernier zone residues of a
RT   humanized anti-human epidermal growth factor receptor murine antibody,
RT   528.";
RL   J. Biol. Chem. 283:1156-1166(2008).
CC   -!- FUNCTION: V region of the variable domain of immunoglobulin heavy
CC       chains that participates in the antigen recognition (PubMed:24600447).
CC       Immunoglobulins, also known as antibodies, are membrane-bound or
CC       secreted glycoproteins produced by B lymphocytes. In the recognition
CC       phase of humoral immunity, the membrane-bound immunoglobulins serve as
CC       receptors which, upon binding of a specific antigen, trigger the clonal
CC       expansion and differentiation of B lymphocytes into immunoglobulins-
CC       secreting plasma cells. Secreted immunoglobulins mediate the effector
CC       phase of humoral immunity, which results in the elimination of bound
CC       antigens (PubMed:22158414, PubMed:20176268). The antigen binding site
CC       is formed by the variable domain of one heavy chain, together with that
CC       of its associated light chain. Thus, each immunoglobulin has two
CC       antigen binding sites with remarkable affinity for a particular
CC       antigen. The variable domains are assembled by a process called V-(D)-J
CC       rearrangement and can then be subjected to somatic hypermutations
CC       which, after exposure to antigen and selection, allow affinity
CC       maturation for a particular antigen (PubMed:20176268, PubMed:17576170).
CC       {ECO:0000303|PubMed:17576170, ECO:0000303|PubMed:20176268,
CC       ECO:0000303|PubMed:22158414, ECO:0000303|PubMed:24600447}.
CC   -!- SUBUNIT: Immunoglobulins are composed of two identical heavy chains and
CC       two identical light chains; disulfide-linked.
CC       {ECO:0000303|PubMed:20176268}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000303|PubMed:20176268,
CC       ECO:0000303|PubMed:22158414}. Cell membrane
CC       {ECO:0000303|PubMed:20176268, ECO:0000303|PubMed:22158414}.
CC   -!- POLYMORPHISM: There are several alleles. The sequence shown is that of
CC       IMGT allele IGHV2-70*01. {ECO:0000305}.
CC   -!- CAUTION: For examples of full-length immunoglobulin heavy chains (of
CC       different isotypes) see AC P0DOX2, AC P0DOX3, AC P0DOX4, AC P0DOX5 and
CC       AC P0DOX6. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC245369; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A02088; MHHUOU.
DR   PIR; A02089; G1HUCO.
DR   PIR; A02090; G2HUCS.
DR   PIR; A02091; G1HUDW.
DR   SMR; P01814; -.
DR   IMGT_GENE-DB; IGHV2-70; -.
DR   BioMuta; IGHV2-70; -.
DR   MassIVE; P01814; -.
DR   PeptideAtlas; P01814; -.
DR   PRIDE; P01814; -.
DR   ProteomicsDB; 51482; -.
DR   ProteomicsDB; 51483; -.
DR   ProteomicsDB; 51484; -.
DR   ProteomicsDB; 51713; -.
DR   Ensembl; ENST00000617374; ENSP00000485200; ENSG00000274576.
DR   GeneCards; IGHV2-70; -.
DR   HGNC; HGNC:5577; IGHV2-70.
DR   neXtProt; NX_P01814; -.
DR   OpenTargets; ENSG00000274576; -.
DR   VEuPathDB; HostDB:ENSG00000274576.2; -.
DR   GeneTree; ENSGT01020000230506; -.
DR   OMA; HMEATAD; -.
DR   PhylomeDB; P01814; -.
DR   PathwayCommons; P01814; -.
DR   Reactome; R-HSA-166663; Initial triggering of complement.
DR   Reactome; R-HSA-173623; Classical antibody-mediated complement activation.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-2168880; Scavenging of heme from plasma.
DR   Reactome; R-HSA-2454202; Fc epsilon receptor (FCERI) signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-5690714; CD22 mediated BCR regulation.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   ChiTaRS; IGHV2-70; human.
DR   Pharos; P01814; Tdark.
DR   PRO; PR:P01814; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P01814; protein.
DR   Bgee; ENSG00000274576; Expressed in stomach and 94 other tissues.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0042571; C:immunoglobulin complex, circulating; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0003823; F:antigen binding; IBA:GO_Central.
DR   GO; GO:0034987; F:immunoglobulin receptor binding; IBA:GO_Central.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0006956; P:complement activation; TAS:Reactome.
DR   GO; GO:0006958; P:complement activation, classical pathway; IBA:GO_Central.
DR   GO; GO:0042742; P:defense response to bacterium; IBA:GO_Central.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0008228; P:opsonization; TAS:Reactome.
DR   GO; GO:0018149; P:peptide cross-linking; TAS:Reactome.
DR   GO; GO:0006911; P:phagocytosis, engulfment; IBA:GO_Central.
DR   GO; GO:0006910; P:phagocytosis, recognition; IBA:GO_Central.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IBA:GO_Central.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013106; Ig_V-set.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00406; IGv; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Immunity; Immunoglobulin; Immunoglobulin domain; Membrane;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:4742735,
FT                   ECO:0000269|PubMed:5449120"
FT   CHAIN           20..119
FT                   /note="Immunoglobulin heavy variable 2-70"
FT                   /evidence="ECO:0000269|PubMed:4742735,
FT                   ECO:0000269|PubMed:5449120"
FT                   /id="PRO_0000059907"
FT   DOMAIN          20..>119
FT                   /note="Ig-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   MOD_RES         20
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:4742735,
FT                   ECO:0000269|PubMed:5449120"
FT   DISULFID        41..116
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17947238"
FT   CONFLICT        16
FT                   /note="W -> G (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        22
FT                   /note="T -> N (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        24
FT                   /note="R -> T (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        32
FT                   /note="K -> R (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        33..35
FT                   /note="PTQ -> ATH (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        34..36
FT                   /note="TQT -> KQP (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        46..51
FT                   /note="FSLSTS -> LSVNTR (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        50..52
FT                   /note="TSG -> GET (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        50..51
FT                   /note="TS -> ST (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        52..54
FT                   /note="GMC -> RMR (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        54
FT                   /note="C -> S (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        56
FT                   /note="S -> A (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        56
FT                   /note="S -> G (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        60
FT                   /note="Q -> R (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        64
FT                   /note="K -> E (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        65
FT                   /note="A -> G (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71..75
FT                   /note="LIDWD -> WDILN (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71
FT                   /note="L -> R (in Ref. 3; AA sequence, 1 and 4; AA
FT                   sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        74
FT                   /note="W -> B (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        77..80
FT                   /note="DKYY -> KFYW (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        81..82
FT                   /note="ST -> GA (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        81
FT                   /note="S -> G (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        81
FT                   /note="S -> N (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        85
FT                   /note="K -> E (in Ref. 3; AA sequence and 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        85
FT                   /note="K -> R (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        89..90
FT                   /note="TI -> AV (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        89
FT                   /note="T -> S (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        93..94
FT                   /note="DT -> ND (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="K -> R (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        102..109
FT                   /note="TMTNMDPV -> SMNTVGPG (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        102..107
FT                   /note="TMTNMD -> IMINVN (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        102..103
FT                   /note="TM -> KV (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103..105
FT                   /note="Missing (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        109
FT                   /note="V -> A (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        119
FT                   /note="I -> M (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        119
FT                   /note="I -> S (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        119
FT                   /note="I -> V (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   NON_TER         119
SQ   SEQUENCE   119 AA;  13260 MW;  2930DA0C57F34F85 CRC64;
     MDILCSTLLL LTVPSWVLSQ VTLRESGPAL VKPTQTLTLT CTFSGFSLST SGMCVSWIRQ
     PPGKALEWLA LIDWDDDKYY STSLKTRLTI SKDTSKNQVV LTMTNMDPVD TATYYCARI
//
